Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality
- PMID: 16845708
Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality
Abstract
Objective: To describe damage accrual and the interconnections between disease activity measures, damage accrual, and death in a Nordic lupus cohort.
Methods: Longitudinal study in the population-based Tromso lupus cohort. Disease activity [SLE Disease Activity Index (SLEDAI)] and disease damage [by Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI)] were recorded for each visit. Weighted average SLEDAI scores (WAS) were calculated to correct for variable observation times. Development of damage (SDI > 0), severe damage (SDI >or= 3), and death were used as separate endpoints. Univariate nonparametric analysis identified and hazard ratios (HR) by Cox regression techniques confirmed the independence of predictors for each outcome.
Results: Through 11.9 years of followup, 72 patients (46%) remained free of damage, 51 (32%) developed moderate damage, and 35 (22%) developed severe damage. SDI scores were higher in 37 nonsurvivors (23.4%; SDI 2.1) than in survivors (SDI 0.9; p < 0.05). Damage accrual was linear throughout the first decade of disease. The only independent predictor for SDI >/= 3 was a WAS score > 3 (hazard ratio 2.34; 95% CI 1.1-4.9). Age > 40 years at diagnosis (HR 5.6, 95% CI 2.4-12.7) and WAS > 3 (HR 2.4, 95% CI 1.2-4.9) were significant predictors for death.
Conclusion: Damage accrual in SLE occurred in 54% of patients in a linear fashion over the first decade of disease. Global disease activity was the main determinant of damage accrual. Accrued damage was not an independent risk factor for death, which was predicted by age > 40 years and WAS > 3.
Similar articles
-
High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus.J Rheumatol. 2002 Jul;29(7):1398-400. J Rheumatol. 2002. PMID: 12136895
-
Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study.Lupus. 2008 Nov;17(11):1042-8. doi: 10.1177/0961203308093829. Lupus. 2008. PMID: 18852231
-
The effect of menopause on disease activity in systemic lupus erythematosus.J Rheumatol. 2006 Nov;33(11):2192-8. Epub 2006 Sep 15. J Rheumatol. 2006. PMID: 16981295
-
Recurrent major infections in juvenile-onset systemic lupus erythematosus--a close link with long-term disease damage.Rheumatology (Oxford). 2007 Aug;46(8):1290-6. doi: 10.1093/rheumatology/kem102. Epub 2007 May 23. Rheumatology (Oxford). 2007. PMID: 17522097 Review.
-
Measuring permanent damage in pediatric systemic lupus erythematosus.Lupus. 2007;16(8):657-62. doi: 10.1177/0961203307078975. Lupus. 2007. PMID: 17711904 Review.
Cited by
-
Impact of the longitudinal quantitative assessment of juvenile systemic lupus erythematosus severity on the disease outcome.Clin Rheumatol. 2021 Feb;40(2):675-682. doi: 10.1007/s10067-020-05252-8. Epub 2020 Jul 7. Clin Rheumatol. 2021. PMID: 32638251
-
Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.Clin Rheumatol. 2017 Feb;36(2):327-333. doi: 10.1007/s10067-016-3492-6. Epub 2016 Nov 26. Clin Rheumatol. 2017. PMID: 27889859
-
Evaluation of damage index and its association with risk factors in patients with systemic lupus erythematosus.J Res Med Sci. 2011 Mar;16 Suppl 1(Suppl1):S427-32. J Res Med Sci. 2011. PMID: 22247729 Free PMC article.
-
Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort.Lupus Sci Med. 2018 Nov 2;5(1):e000287. doi: 10.1136/lupus-2018-000287. eCollection 2018. Lupus Sci Med. 2018. PMID: 30538818 Free PMC article.
-
Update on Antiphospholipid Syndrome: Ten Topics in 2017.Curr Rheumatol Rep. 2018 Mar 15;20(3):15. doi: 10.1007/s11926-018-0718-4. Curr Rheumatol Rep. 2018. PMID: 29541874 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical